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The vaccinia virus (VACV) strain Western Reserve C16 protein has been characterized and its
effects on virus replication and virulence have been determined. The C16L gene is present in the
inverted terminal repeat and so is one of the few VACV genes that are diploid. The C16 protein is
highly conserved between different VACV strains, and also in the orthopoxviruses variola virus,
ectromelia virus, horsepox virus and cowpox virus. C16 is a 37.5 kDa protein, which is expressed
early during infection and localizes to the cell nucleus and cytoplasm of infected and transfected
cells. The loss of the C16L gene had no effect on virus growth kinetics but did reduce plaque
size slightly. Furthermore, the virulence of a virus lacking C16L (vDC16) was reduced in a murine
intranasal model compared with control viruses and there were reduced virus titres from 4 days
post-infection. In the absence of C16, the recruitment of inflammatory cells in the lung and
bronchoalveolar lavage was increased early after infection (day 3) and more CD4
+ and CD8
+ T
cells expressed the CD69 activation marker. Conversely, late after infection with vDC16 (day 10)
there were fewer T cells remaining, indicating more rapid clearance of infection. Collectively,
these data indicate that C16 diminishes the immune response and is an intracellular
immunomodulator.
INTRODUCTION
Vaccinia virus (VACV) is the prototypical member of the
genus Orthopoxvirus (OPV) of the Poxviridae and is
famous as the live vaccine used to eradicate smallpox, an
extinct human disease caused by variola virus (VARV)
(Fenner et al., 1988). Following the eradication of
smallpox, VACV continues to be studied intensively
because of its development as a vaccine vector (Panicali
et al., 1983; Smith et al., 1983), and because of its
fascinating interactions with the host cell and immune
system (Seet et al., 2003; Haga & Bowie, 2005). In this
study, we have characterized the C16L gene of VACV strain
Western Reserve (WR) and the encoded protein.
The VACV WR C16L gene is located in the inverted
terminal repeat (ITR) at both ends of the VACV genome.
Many genes within and adjacent to the ITRs encode
proteins that modulate the host immune response or
interactions with the host cell. For example, the gene
upstream of C16L encodes the VACV growth factor
(Twardzik et al., 1985; Buller et al., 1988), which promotes
cell growth, and the gene two genes downstream encodes
the interleukin (IL)-18-binding protein (Smith et al., 2000;
Symons et al., 2002; Reading & Smith, 2003). The C16L
gene is predicted to encode a 331 aa protein with a mass of
37.5 kDa (www.poxvirus.org). There are highly conserved
orthologues of C16 in several other OPVs, suggesting an
important function, and bioinformatic analysis identified a
conserved 6 aa sequence at the C terminus of C16 that is
present in the same region of the IL-1 receptor antagonist
(IL-1ra) protein (Kluczyk et al., 2002). This 6 aa sequence
is also conserved in the VACV strain Copenhagen
orthologue of C16 (termed C10) (Goebel et al., 1990),
and in orthologues in other OPVs (www.poxvirus.org).
This sequence is critical for the ability of IL-1ra to
antagonize signalling from the IL-1 receptor (IL-1R) and
prompted the proposal that the VACV protein might act as
a secreted viral IL-1ra and inhibit signalling from the IL-1R
by receptor blockade (Kluczyk et al., 2004).
The goals of this study were to characterize the C16
protein, determine its location and investigate if it affects
virus replication or virulence. A VACV deletion mutant
lacking both copies of the C16L gene (vDC16) and a
revertant virus (vC16Rev) in which the C16L gene was
reinserted into the deletion mutant were constructed. Data
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replication, but promotes VACV virulence in a murine
intranasal (i.n.) model and delays the infiltration and
activation of cells in the infected lungs. As such, it
represents an intracellular virulence factor that functions
as an immunomodulator.
METHODS
Cell culture. BS-C-1, TK
2143 and HeLa cells were grown at 37 uCi n
a5 %C O 2 atmosphere in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum (FBS; Gibco). The source
of VACV strain WR was described previously (Alcami & Smith,
1992).
Construction of plasmid vectors. A cassette containing the
Escherichia coli guanylphosphoribosyl transferase (Ecogpt) gene fused in-
frame with the enhanced green fluorescent protein (EGFP) gene and
downstream of synthetic early/late VACV promoter was assembled as
follows. The Ecogpt gene was amplified by PCR with primers AF1 (59-
AGTCGAATTCATAGCGAAAAATACATCGTCACCTGGGAC-39)a n d
AF2 (59-GCGCTAGCGGATCTGAGCGACCGGAGATTGGCGGG-39)
and pGpt07/14 as template (Boyle & Coupar, 1988). The EGFP gene
was amplified by PCR using primers AF3 (59-CGCCAATCTCC
GGTCGCTCAGATCCGCTAGCGCTACCG-39) and AF4 (59-AGTCCC
CGGGATAAAAATTTACTTGTACAGCTCGTCCATGCCGAG-39)a n d
pEGFPC2 (BD Biosciences) as template. These PCR products were
joined together by splice overlap extension(Horton et al., 1989) by using
primers AF1 and AF4. The product was digested with SmaIa n dEcoRI
and cloned into pSEL (Bartlett et al., 2004) downstream of a VACV
synthetic early/late promoter (Davison & Moss, 1990) forming pSEL-
Ecogpt/EGFP (also called pAFA).
The flanking regions of the C16L gene were amplified from VACV WR
genomic DNA by using primers AF5 (59-GACGGTATGTATT
GTAGATGCTCTCATGG-39) and AF6 (59-CGTCAAACAATCATTCC
CGGGTATAATATCTAGAGGTAGAGG-39) for the 395 bp upstream
region and primers AF7 (59-CCTCTAGATATTATACCCGGGAATGA
TTGTTTGACGAATCACG-39) and AF8 (59-GGAGATCATACTACC
ACAACTTATTATTATGC-39) for the 383 bp downstream flanking
region. These PCR products were ligated together using a SmaIs i t e
(indicated in italics) and then cloned into pGEMT by restriction
digestion with EcoRI and NotIt of o r mp G E M T - DC16L plasmid
(pAFC).
The cassette containing pSEL driving Ecogpt/EGFP was excised from
pAFA with SmaI and ligated into SmaI-digested pAFC to place the
Ecogpt/EGFP cassette between the C16L flanking regions. This
resultant plasmid, pGEMT-DC16L-Ecogpt/EGFP (also called pAFB)
was used to construct the C16L deletion virus. To make a revertant
virus, in which the C16L gene was reinserted into its natural loci, the
C16L gene and flanking regions were amplified from VACV strain
WR genomic DNA by using primers AF5 and AF8. The product was
digested with EcoRI and NotI, ligated into pGEMT that had been
digested with the same enzymes and termed pAFD.
The fidelity of all PCR-generated DNA sequences was confirmed by
sequencing.
Construction of recombinant viruses. A VACV deletion mutant
wherein both copies of the C16L gene were replaced with the Ecogpt/
EGFP cassette was constructed by transfecting pAFB into CV-1 cells
that had been infected with a plaque purified VACV WR (vC16).
Recombinant viruses were selected in the presence of mycophenolic
acid, xanthine and hypoxanthine (Boyle & Coupar, 1988). These
recombinant viruses were also screened for EGFP expression by
fluorescent microscopy and, after further rounds of plaque purifica-
tion on BS-C-1 cells, were analysed by PCR to ensure replacement of
both copies of the C16L gene with the Ecogpt/EGFP cassette. The
resultant plaque-purified virus was called vDC16/Ecogpt/EGFP.
To remove the Ecogpt/EGFP cassette from the C16L locus, plasmid
AFC was transfected into vDC16/Ecogpt/EGFP-infected cells and
Ecogpt-negative viruses were selected using 6-thioguanine on D-
98OR cells (Kerr & Smith, 1991). The deletion mutant virus was
called vDC16. A revertant virus was constructed in a similar manner
by transfection of plasmid AFD into vDC16/Ecogpt/EGFP-infected
cells to create vC16Rev. Viruses were analysed by PCR using primers
AF5 and AF8 to characterize the C16L locus. Genomic DNA was also
analysed by restriction enzyme digestion and electrophoresis on a
0.6% agarose gel.
Expression of C16 in E. coli and production of anti-C16 rabbit
serum. The C16 ORF was amplified by PCR using primers AF9 (59-
AGATCCATGGGTGATATTTACGACGATAAAGGTCTACAG-39)a n d
AF10 (59-AGATGAATTCCCGCTGCCGCGCGGCACCAGTTTCGG
CATATTAAAGTAAAATC-39) and VACV WR DNA as template. The
product was digested with NcoIa n dEcoRI (indicated in italics) and
cloned into NcoI- and EcoRI-digested pET28a (Novagen) and the
resultantplasmid,pET28a-C16L-CHis,wastermedpAFE.Recombinant
C16 protein was expressed from E. coli strain BL21 according to the
vector manufacturer’s instructions (Novagen) and was purified by
nickel chelate and ion-exchange chromatography as described for the
A41 protein (Ng et al., 2001). The purified protein (100–200 mgw i t ha n
estimated purity of 90%) was injected into New Zealand White rabbits
to produce anti-C16 serum (Harlan Sera Laboratories).
Immunoblotting. Cells were infected with the indicated viruses at 10
p.f.u. per cell and cell lysates and supernatants were prepared as
described previously (Bartlett et al., 2002). Antibodies used included
rabbit polyclonal sera against VACV proteins C16 (1:2000) (see
above), A41 (1:1000) (Ng et al., 2001) and A56 (1:1000), or mouse
monoclonal antibody AB1.1 against D8 (1:1000) (Parkinson &
Smith, 1994). Secondary antibodies and detection systems were as
described previously (Bartlett et al., 2002).
Cell fractionation. BS-C-1 cells were infected at 0.1 p.f.u. per cell for
48 h, scraped from the dish and collected by centrifugation (800 g,
5 min). The cell pellet was resuspended in hypotonic buffer (10 mM
Tris/HCl, pH 9.0) and disrupted by Dounce homogenization. The
nuclei were removed by centrifugation (300 g, 5 min) and the
cytoplasmic fraction (supernatant) was removed. Nuclei were washed
four times in 10 mM Tris/HCl, pH 9 before incubation in RIPA
buffer for 10 min. The mixture was centrifuged (1500 g, 10 min) and
the supernatant retained as the nuclear fraction.
Immunofluorescence. HeLa cells were grown on sterilized glass
coverslips (borosilicate glass; BDH) in six-well plates and infected at
5 p.f.u. per cell. Where indicated, 1 ng leptomycin B (Sigma-Aldrich)
ml
21 was added to the cells for 4 h (Wolff et al., 1997). Cells were
washed, fixed, permeablised and blocked as described previously
(Chen et al., 2006). Cells were stained with anti-C16 (1:100) or anti-
p65 (1:50; Santa Cruz) at room temperature for 1 h, followed by
secondary antibody staining and mounting as described previously
(Chen et al., 2006).
Virus growth curves. Monolayers of BS-C-1 cells were infected with
either 10 or 0.01 p.f.u. per cell for measurement of one-step or multi-
step growth kinetics, respectively, as described previously (Chen et al.,
2006).
Murine i.n. and intradermal models of infection. Female BALB/c
mice (n55, 6–8 weeks old) were infected i.n. with 5610
3 p.f.u. and
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Smith, 1992). Female C57BL/6 mice (n55, 6–8 weeks old) were
inoculated intradermally (i.d.) in the ear pinnae with 1610
4 p.f.u. as
described previously (Tscharke & Smith, 1999; Tscharke et al., 2002).
Analysis of cell populations of infected organs. Mice were
infected i.n. with 1610
4 p.f.u. and at the indicated time post-
infection (p.i.) were sacrificed, and the bronchial alveolar lavage
(BAL) and lung tissue were processed as described previously (Clark
et al., 2006; Jacobs et al., 2006). Live cells in BAL or lung samples
were counted, washed with FACS buffer (0.1% BSA, 0.1% NaN3 inz
PBS), blocked and stained with appropriate combinations of
fluorescein isothiocyanate-, phycoerythrin- or tricolour-labelled
antibodies. These were grouped into anti-CD25, anti-CD69, anti-
CD3, anti-CD8, anti-CD4 for T lymphocytes, anti-Ly6G on
neutrophils, anti-DX5 on natural killer cells, anti-F480 on macro-
phages and the relevant isotype controls (BD biosciences) as
described previously (Jacobs et al., 2006). The presence of cell-
surface markers was determined on a FACScan flow cytometer with
CellQuest software (BD Biosciences). A lymphocyte gate was used to
analyse data from at least 20000 events.
Murine vaccination and challenge analysis. Female BALB/c mice
(n55, 6–8 weeks old) were vaccinated i.d. in the ear pinnae with
1610
4 p.f.u. of the indicated virus, and, 28 days later, were
challenged i.n. with 5610
6 p.f.u. of VACV WR and monitored as
described previously (Clark et al., 2006).
Statistical analysis. Student’s t-test (two tailed, unpaired) was used
to examine the significance of raw data.
RESULTS
Construction of C16L deletion mutant and
revertant viruses
To study the function of the C16 protein, a VACV strain
WR mutant lacking both copies of the C16L gene, vDC16,
was constructed (Methods) from plaque-purified VACV
WR (vC16). The isolation of this virus demonstrated that
the C16L gene was non-essential for virus replication. A
revertant virus in which the C16L gene was reinserted into
both ITRs, vC16Rev, was also constructed. PCR using
primers for the C16L gene locus confirmed the presence of
the C16L gene in vC16 and vC16Rev, and its absence in
vDC16 (Supplementary Fig. S1 available in JGV Online).
Analysis of genomic DNA by restriction enzyme digestion
and agarose gel electrophoresis showed that the only
discernible change between the viruses was caused by
alteration to the C16L loci (data not shown).
Analysis of C16 expression
Immunoblot analysis using anti-C16 (Methods) identified
25 and 37 kDa proteins in extracts of cells infected with
vC16 but not with vDC16 (Fig. 1a) or in mock-infected
cells (Fig. 2a). These proteins were found in cell lysates and
not in the concentrated culture supernatant, whereas the
secreted protein A41 (Ng et al., 2001) was present in the
culture medium and D8, a 35 kDa intracellular mature
virus (IMV) membrane protein (Niles & Seto, 1988), was
in the cell lysates.
To determine when C16 is expressed during infection, cells
were infected in the presence or absence of cytosine
arabinoside (AraC), an inhibitor of viral DNA replication
and therefore late protein expression, and extracts of cells
were analysed by immunoblotting (Fig. 1b). The 37 kDa
C16 protein was detected from 2 h p.i., and at all times
thereafter. Notably, it was expressed in the presence of
AraC, indicating expression early during infection. In
contrast, AraC blocked the expression of A56, a protein
expressed predominantly late during infection (Brown et
al., 1991). Notably, the 25 kDa C16 protein was present
only late during infection and its formation was ablated in
the presence of AraC.
The intracellular localization of the C16 protein was
examined by biochemical fractionation of cells followed
by immunoblotting (Fig. 2a) and immunofluorescence
(Fig. 2b). Immunoblotting showed that cellular proteins
tubulin and lamin A+C were present in the cytoplasmic or
nuclear fraction, respectively, as expected. In contrast, the
37 kDa C16 protein was in both nuclear and cytoplasmic
fractions after infection with vC16 and vC16Rev, but, even
after longer exposure of the film, the 25 kDa C16 protein
localized exclusively to the cytoplasm. For comparison, the
VACV protein D8 was only in the cytoplasm.
Fig. 1. Characterization of C16 expression.
BS-C-1 cells were infected with vC16 (a and
b) or vDC16 (a) in the presence (+)o f4 0mg
AraC ml
–1 where indicated (b). Samples were
analysed by SDS-PAGE and immunoblotting
with antibodies against the indicated proteins.
(a) Infected cell supernatants were removed at
16 h p.i., concentrated and equivalent
amounts of cell lysate (C) and supernatant
(S) were analysed by immunoblotting. (b) Cell
lysates were prepared at the indicated times
p.i. The positions of molecular mass marker are
shown in kDa.
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cytoplasm and nucleus [Fig. 2b(i)]. There was minimal
background immunofluorescence in vDC16-infected cells
(data not shown). The partial nuclear localization was
investigated further using leptomycin B, an inhibitor of
active nuclear export. In the presence of leptomycin B, the
great majority of C16 and p65 were present in the nucleus
[panels (v) and (vi), suggesting active transport rather than
diffusion through the nuclear pores (Fig. 2b)]. This
localization pattern and active transport were similar in
C16-transfected cells (data not shown).
Computational analysis of the C16L gene
The VACV WR C16L gene is present in both ITRs (GenBank
accession nos YP_232892 and YP_233091) and is predicted to
encode a protein without a transmembrane domain or signal
peptide (www.poxvirus.org). Computational analysis found no
cellular proteins with similarity to the VACV WR C16 protein,
with the exception of the C-terminal peptide in the IL-1ra
protein. However, C16 is highly conserved in several OPVs
including variola virus (VARV), cowpox virus (CPXV),
ectromelia virus (ECTV) and horsepox virus (HSPV). C16 is
diploid in some strains of VACV, but not in other OPVs. In
monkeypox virus (MPXV), camelpox virus (CMLV) and
taterapox virus (TATV) the reading frame of the C16L
orthologue is disrupted by mutation into shorter fragments.
The phylogenetic relationships of these proteins are shown in a
rooted tree (Fig. 3a) produced from the aligned amino acid
sequences. Group I proteins share 95–99% amino acid identity
and these proteins all have the C-terminal VTRFYF sequence,
which is present in the IL-1ra protein (Kluczyk et al., 2004).
Another group of more distantly related OPV proteins,
typified by protein C4 from VACV WR, was identified and is
shown as group II (Fig. 3a). The C4 protein family is also
conserved in several OPVs (VACV, VARV, CMLV, TATV,
MPXV and CPXV) and these have 40–44% amino acid
identity to VACV WR C16. The degree of similarity between
C16 and C4 is greatest in the C-terminal 100 aa, where these
proteins share 55% identity. Within the C4 group the
proteins are highly conserved (95–99% identity). Notably,
C4 is encoded by CMLV, TATV and MPXV viruses that lack
C16. The close similarity between the C4 and C16 proteins
within OPVs suggest that they are likely to have been
generated by a gene duplication event followed by diver-
sification. The third group (III) of proteins (Fig. 3a)
comprises more distantly related proteins from other
chordopoxviruses including goatpox virus (GPXV), lumpy
skin disease virus (LSDV), sheeppox virus (all genus
Capripoxvirus), fowlpox virus (genus Avipoxvirus), Yaba
monkey tumor virus (genus Yatapoxvirus) and deerpox virus
(DPXV) (unclassified). These proteins have 26–37% amino
acid identity (49–61% similarity) to C16, and are closer to
C16 than C4. Within the groups II and III proteins, the IL-
1ra-like sequence, VTRFYF, is partially conserved with the
consensus sequence VT(R/K)-Y-.
The expression of C16 by 14 VACV strains, two strains of
CPXV and CMLV strain CMS was investigated by immuno-
blotting (Fig. 3b). Protein(s) recognized by the anti-C16
serum were expressed by all 14 VACV strains and both
strains of CPXV, but not by CMLV or vDC16. The latter
observation demonstrated that the anti-C16 antibody does
notrecognizetherelatedC4proteinencodedbyVACVstrain
Fig. 2. Localization of C16 in infected cells. (a) Immunoblotting. BS-C-1 cells were infected with the indicated viruses for 16 h
and nuclear and cytoplasmic fractions were analysed by immunoblotting with antibodies against the indicated proteins. The
positions of molecular mass marker are shown in kDa. (b) Immunofluorescence. Cells were infected with vC16 for 16 h and
then incubated in the presence or absence of leptomycin B for 4 h. The localization of C16 [(i) and (v)] and NF-kB subunit p65
[(ii) and (vi)] were analysed. Phase-contrast [(iii) and (vii)] and merged images [(iv) and (viii)] are also shown. Bar, 5 mm.
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Dairen, Copenhagen and Tashkent) produced proteins of 37
and 25 kDa that were recognized by the anti-C16 antibody.
These are both encoded by the C16L gene because they were
absent in cellsinfectedbyvDC16 and wereexpressed byvC16
and vC16Rev controls. The smaller polypeptide might be
derived from the 37 kDa protein by proteolytic cleavage or
(less likely) it might be generated by different translation
initiation and its significance is unknown.
C16 is non-essential in cell culture
The isolation of vDC16 demonstrated that C16 is not
essential for VACV replication. To determine if deletion of
Fig. 3. Conservation of C16. (a) A rooted
phylogenetictreeofVACV WRC16 and related
poxvirus proteins. Amino acid sequences from
C16-like proteins (www.poxvirus.org) were
aligned using the CLUSTAL W programme and a
rooted tree was derived from this alignment
using PHYLIP (phylogeny inference package,
version 3.67). The bootstrap values for 1000
replicate samplings are indicated, values of
1000 are indicated by *. Bar, Branch length of
0.1 substitutions per site. (b) BS-C-1 cells were
infected with 14 VACV strains, two CPXV
strains [Brighton Red, (BR) and elephantpox-2]
and CMLV strain CMS. Cell lysates were
prepared 16 h p.i., separated by SDS-PAGE
and immunoblotted using antibody against C16
or D8. Molecular mass marker is shown in kDa.
Vaccinia C16 protein: an intracellular virulence factor
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spread, the growth of vDC16 was compared with wild-type
and revertant controls. Plaques formed by vDC16 were
slightly smaller (P,0.05) than controls in BS-C-1 and RK-
13 cells (Fig. 4a). To investigate if the reduced plaque size
was due to reduced virus titres or reduced virus spread, the
replication kinetics were analysed after low (0.01) or high
(10) m.o.i. However, no difference was observed between
vDC16 and controls (Fig. 4b and data not shown). Virus
plaque formation is influenced by the production of actin
tails beneath cell-associated enveloped virus particles on
the cell surface (Smith et al., 2002, 2003), and so the
formation of actin tails by vDC16 was analysed by confocal
microscopy. However, no difference between vDC16 and
controls was observed (data not shown) and so the reason
for the small difference in plaque size remains unknown.
C16 affects virus virulence in the murine i.n. model
The virulence of vDC16 was compared with control viruses
in two murine models. In an i.d. model, no significant
difference in lesion size or cell recruitment was observed in
animals infected with vDC16 at 10
4 p.f.u. compared to
control viruses (Supplementary Fig. S2 available in JGV
Online and unpublished data). However, in an i.n. model,
vDC16 induced significantly (P,0.05) less weight loss and
milder signs of illness compared with controls (Fig. 5a and
b) between days 6 and 11. Moreover, although all viruses
replicated initially to similar titres (day 2) there was
significantly (P,0.05) less infectious virus in lungs infected
by vDC16 from day 4 p.i. onwards (Fig. 5c and d). This
accelerated virus clearance after infection with vDC16
compared with controls suggested a more effective antiviral
host response, and therefore the cellular inflammatory
response in lungs was analysed by flow cytometry.
C16 affects immune cell recruitment in the murine
i.n. model
Cells in infected lungs and BAL were extracted, quantified
by trypan blue exclusion and identified by flow cytometry
(Fig. 6a). This revealed a statistically (P,0.05) higher
number of cells in vDC16-infected BALs at day 3 p.i.,
compared with controls. By day 7, the cell numbers had
equalized between the viruses, whereas at day 10, there
were fewer lymphocytes present in the BAL of mice
infected with vDC16. To test whether this early increase in
lymphoid cells was due to an enhanced recruitment of a
particular lymphoid subset, the percentage of macrophages
(Fig. 6b), neutrophils (Fig. 6c), natural killer cells and
CD4
+ and CD8
+ T lymphocytes (data not shown) present
was analysed. This showed a slightly greater number of all
cell types examined in the vDC16-infected BAL at day 3,
but there was no dramatic increase in any lymphoid subset.
Next,the recruitment and activationofT cells(CD3
+)i nt h e
lungs was investigated by staining for CD3, CD4, CD8 and
CD69 (Fig. 6d–f). Natural killer cell (DX5
+) recruitment in
the lungs was also analysed and showed no significant
variation between vDC16 and control viruses
(Supplementary Fig. S3 available in JGV Online). T-cell
analysis showed that at day 3 more of the CD4
+ and CD8
+
T cells, recruited to the site of infection with vDC16, were
activated (CD69
+) compared with controls. By day 7, there
was no difference in the number of activated T lymphocytes
after infection with the different viruses. However, by day 10
there was a reduction in CD4
+ and CD8
+ T cells present
Fig. 4. vDC16 plaque formation and growth kinetics. (a) Plaque
size. Monolayers of BS-C-1 or RK-13 cells were infected with the
indicated viruses to give well separated plaques and at 72 h p.i.
the size of 50 plaques was measured for each virus using Adobe
Photoshop 7.0. Data are expressed as the average area (measured
in pixels) (10
5)±SD.* 5P,0.05 for vDC16 compared with both
vC16 and vC16Rev. (b) Growth curves. BS-C-1 cells were
infected at 0.01 p.f.u. per cell and aliquots of culture medium
(mainly extracellualr enveloped virus) or infected cells (mainly IMV)
were collected at the indicated times p.i. The cells were frozen and
thawed three times, sonicated and virus infectivity was titrated by
plaque assay. Data are presented as the mean log10 p.f.u.±SD.
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is that the host response to infection with vDC16 is
accelerated compared with controls, so that early p.i. there
are more cells in vDC16-infected tissues and these show a
greater degree of activation, whereas at late times there are
fewer cells because the infection is being cleared sooner. By
inference, the C16 protein may function to diminish the
innate response to infection.
Vaccination and challenge with vDC16
To characterize further the immune response to infection
with vDC16, the effectiveness of this virus as a vaccine was
compared with that of the control viruses (Fig. 7). Mice were
vaccinated i.d. withthe indicatedvirusesandwere challenged
with VACV WR 28 days later. The challenge dose was 500
LD50 for BALB/c mice of this age and hence even vaccinated
mice began to lose weight rapidly. Weight loss reached its
maximum at day 3 post-challenge when the average weight
loss of the three immunized groups (vC16, vDC16 and
vC16Rev) was 20–21%. However, under the conditions
tested there was no difference in the protection afforded by
immunization with vDC16 compared to the control viruses.
DISCUSSION
A characterization of the C16 protein from VACV strain WR
and the effects of this protein on virus replication, virulence
and immunogenicity are reported. Bioinformatic analysis
indicated that very closely related proteins (95–99% amino
acid identity) are encoded by five OPV species and that the
gene is present, but disrupted, in three others. In addition,
C16 is related to another family of OPV proteins exemplified
by C4 from VACV WR, and a more distantly related group
from other chordopoxviruses. C16 was expressed by all
VACV and CPXV strains tested and was synthesized early
during infection. This early expression profile is consistent
with the analysis of the C16L promoter(data not shown) and
a genome-wide transcriptome analysis that detected C16
mRNA by 1 h p.i. (Assarsson et al., 2008). C16 is shuttled
actively between the cytoplasm and nucleus but lacks a
recognizable nuclear localization signal and nuclear export
signal, suggesting it might be transported in a complex with
another protein. The partial nuclear localization of C16 is
interesting because it is one of only a few nuclear proteins
encoded by VACV, which replicates in the cytoplasm.
Another example is the E3 protein (Yuwen et al., 1993) that
binds dsRNA (Chang et al., 1992) and contributes to
virulence (Brandt & Jacobs, 2001). In contrast, a group of
other VACV proteins that affect transcription of host nuclear
factor kappa B (NF-kB)-responsive genes function from
within the cytoplasm (Bowie et al., 2000; Bartlett et al.,2 0 0 2 ;
Shisler & Jin, 2004; Chen et al., 2006, 2008). There are also
reportsofendogenousnuclearproteinsbeingrecruitedtothe
cytoplasm during VACV infection (Oh & Broyles, 2005).
The intracellular location of the C16 protein makes its
postulated function as an IL-1ra-like protein that
mediates extracellular blockade of signalling from the
IL-1R (Kluczyk et al., 2002, 2004) unlikely. C16 would
Fig. 5. Virulence in murine i.n. model. BALB/c
mice (n55) were infected with the indicated
viruses and their weights (a) and signs of
illness (b) were measured daily (Methods). (a)
Weights. Data are expressed as the
percentage±SD of the mean weight of the
same group of animals on day 0. (b) Signs of
illness. The mean score±SEM of each group of
animals is shown. The horizontal bar indicates
days on which the weight loss or signs of
illness induced by vDC16 was statistically
different (P,0.05) from both vC16 and
vC16Rev. (c and d) Virus titres in lungs. (c)
Mice were infected i.n. as in (a) and, at the
indicated times, groups (n55) were sacrificed
their lungs were removed and infectious virus
per ml of lung homogenate was determined by
plaque assay. (d) Data from (c) are presented
as percentages of the virus titres in the vC16-
infected lungs for that day±SD.* 5P,0.05 for
vDC16 compared to both vC16 and vC16Rev.
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1R after release due to lysis of infected cells, and while
this might happen very late during infection, such a
function is unlikely to be its primary role given its early
expression. However, there are also intracellular (ic) IL-
1ra proteins, produced by differential splicing (Butcher et
al., 1994; Malyak et al., 1998a, b) and whose functions
remain poorly defined. These icIL-1ra isoforms were
reported to downregulate the IL-1 pathway (Watson et
al., 1995; Arend et al., 1998; Banda et al., 2005).
Moreover, the precursor form of IL-1a, pro-IL-1a,c a n
localize to (Wessendorf et al., 1993) and function within
the nucleus (Cheng et al., 2008) and icIL-1ra may regulate
these functions. It is therefore more likely that C16
functions by mimicking icIL-1ra. Interestingly, the
deerpox virus protein 054 shares 89% amino acid
identity with the secreted IL-1ra protein from Bos
Taurus (Afonso et al., 2005) and is substantially more
likely to mimic extracellular IL-1ra activity than C16, but
does not have a counterpart in VACV or other OPVs.
VACV already targets the IL-1 pathway by several mechanisms,
indicating the importance of IL-1 against poxvirus infections.
VACV restricts the formation of IL-1b in infected cells by
expressing a caspase 1 inhibitor (Dobbelstein & Shenk, 1996;
Kettle et al., 1997) and blocks the function of IL-1bsystemically
by the expression of a soluble IL-1bR( A l c a m ı ´ & Smith, 1992;
Spriggs et al., 1992; Alcamı ´ & Smith, 1996). Furthermore,
VACV expresses intracellular proteins A46 (Bowie et al., 2000;
Stack et al., 2005), A52 (Bowie et al., 2000; Harte et al., 2003;
Graham et al., 2008), N1 (Bartlett et al., 2002; DiPerna et al.,
2004;Coorayetal.,2007;Grahametal.,2008)andB14(Chenet
al., 2006, 2008) that inhibit IL-1a-o rI L - 1 b-induced signalling
from the IL-1R that would otherwise activate NF-kB.
A virus deletion mutant, vDC16, formed a slightly smaller
plaquewhencomparedwithwild-typeandrevertant controls,
butreplicatednormallyinthecelllinesanalysedandin vivo to
reach equivalent titres at 2 days p.i. However, there was no
defect in virus-induced actin tail formation, a pre-requisite
for efficient cell-to-cell spread. Hence, the basis for this small
Fig. 6. Characterization of infiltrating leuko-
cytes. Cells were extracted from the BAL (a–c)
and lungs (d–f) of infected mice (n55),
counted and analysed by flow cytometry.
Asterisks indicate where data for vDC16 are
significantly different from the vC16 and
vC16Rev (P,0.05, Student’s t-test). (a) Total
numbers of viable cells in the BAL. Data are
means of cell counts±SD. (b and c)
Macrophages (b) and neutrophils (c) were
identified and quantified by FACS. (d–f).
Lungs. The number and activation status
(CD69
+) of CD4
+ and CD8
+ T cells were
analysed by FACS and are presented as a
percentage of the total cells present.
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consistent with the presence of C16 in both the nucleus and
cytoplasm, is that C16 might modulate intracellular signalling
pathways and that, over several cycles of infection, replication,
release and reinfection, this provides an advantage for the
v i r u s .S u c has u bt l ed i f f e r e n c em ig h tn o tb em a n i f e s te dd u r i n g
analysis of replication kinetics. A precedent for this was
reported with the B14 protein of VACV WR. A mutant
lacking B14 replicated normallyin cellculture and in vivo,b u t
produced a slightly small plaque in cell culture and an altered
inflammatory response in vivo (Chen et al., 2006). This was
explained by the observation that B14 interacts with the IkB
kinase complex and inhibits NF-kB activation (Chen et al.,
2008). Most VACV immunomodulatory proteins, like B14,
are expressed early during infection and the early expression
of C16 would be consistent with such a role.
T h ed e l e t i o no fC 1 6f r o mt h eV A C VW Rg e n o m er e d u c e d
virus virulence in a murine i.n. model (systemic infection) but
not in an i.d. (local infection) model. This attenuation was
characterized by significant reductions in virus-induced
weight loss, signs of illness and virus titres. Although, vDC16
virus titres in infected lungs were equivalent to control virus-
infected lungs at 2 days p.i, at later times the virus titres were
considerablyreducedinvDC16-infectedtissues.Thisindicated
that, in the absence of C16, the virus can replicate efficiently in
vivo, but, in the absence of C16, virus clearance is accelerated.
Investigation of this attenuated phenotype by analysis of
lymphoid cells within infected tissue indicated a difference in
the number and properties of the infiltrating cells and the
kinetics of their recruitment. At 3 days p.i., the number of
infiltrating cells was greater after infection with vDC16, and
more CD4
+ and CD8
+ T cells were activated (CD69
+). By
day 7, the number of cells present and the proportion that
were activated were equivalent for all viruses. However, by
day 10 the total number of infiltrating cells and the number of
CD4
+ and CD8
+ T cells were reduced after infection with
vDC16, consistent with more rapid resolution of the infection.
The accelerated recruitment and activation of T cells early
after infection fits with the diminished virus titres observed
from day 4 p.i., and with the reduced weight loss and signs of
illness. The recruitment of leukocytes to sites of inflammation
is dependent on the expression of chemokines and cytokines.
It follows that C16 is either directly or indirectly influencing
the expression or function of such inflammatory mediators.
The intracellular location of C16 suggests that it might
mediate such an effect by modulating intracellular signalling
pathways and this possibility is currently under investigation.
Despite the reduction of virulence of vDC16 in the i.n. model
and the difference in T-cell recruitment and activation,
vDC16 was as effective as wild-type and revertant controls in
inducing protective immunity against subsequent virus
challenge with an otherwise lethal dose of VACV strain
WR. The vDC16 phenotype (reduced virulence yet undi-
minished immunogenicity) make VACV strains lacking the
C16L gene attractive vaccine candidates.
In summary, C16 is an intracellular virulence factor, which
modulates the host response to infection. Investigation of
its role in virus virulence should provide further insight
into host–virus interactions and viral immunomodulation.
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